Reversible posterior leukoencephalopathy syndrome (RPLS) is clinical radiologic condition associated with neurological symptoms and cerebral white matter edema.
It has been associated with uncontrolled hypertension, eclampsia, immunosuppressants, and more recently the use of antiangiogenic drugs. Sunitinib is an inhibitor of the vascular endothelial growth factor receptor widely used in the treatment of metastatic renal cell carcinoma (RCC). We report a rare case of RPLS occurring on therapy with sunitinib in a patient with RCC. Our aim is to highlight the importance of considering RPLS as a diagnostic possibility and to hold sunitinib for RCC patients presenting with neurologic symptoms.
Written by:
Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Are you the author?
Department of Oncology, Real Hospital Portugues, 52010 Recife, PE, Brazil; Cedar Valley Cancer Center, Waterloo, IA 50701, USA; American University of the Caribbean, Coral Gables, FL 33134, USA; Department of Radiology, Real Hospital Portugues, 52010 Recife, PE, Brazil; Department of Neurosurgery, Real Hospital Portugues, 52010 Recife, PE, Brazil.
Reference: Case Rep Oncol Med. 2014;2014:952624.
doi: 10.1155/2014/952624
PubMed Abstract
PMID: 24900933
UroToday.com Renal Cancer Section
